Skip to main content
Premium Trial:

Request an Annual Quote

ReadCoor: Dennis Flannelly

Multi-omic spatial sequencing company ReadCoor has appointed Dennis Flannelly to its board of directors. Flannelly is currently head of precision medicine for US oncology at Merck, known as MSD outside of the US and Canada. Prior to joining Merck, Flannelly served in leadership roles at PerkinElmer, most recently as VP and general manager of the immunodiagnostics business, and previously as VP of maternal-fetal health. Flannelly has also served as global director of clinical marketing for Thermo Fisher Scientific's immunodiagnostics business. He also served as the head of US marketing for Thermo Fisher.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.